Rey-Ting Guo

Rey-Ting Guo

Auto-generated profile, based on publicly available information

Rey-Ting Guo

Zhejiang Key Laboratory of Medical Epigenetics, Department of Immunology and Pathogen Biology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
XHXu Han
Xu Han
WLWeidong Liu
Weidong Liu
JHJian-Wen Huang
Jian-Wen Huang
JMJiantao Ma
Jiantao Ma
YZYingying Zheng
Yingying Zheng
RGRey-Ting Guo
Rey-Ting Guo
PET hydrolase (PETase), which hydrolyzes polyethylene terephthalate (PET) into soluble building blocks, provides an attractive avenue for the bioconversion of plastics. Here we present the structures of a novel PETase from the PET-consuming microbe Ideonella sakaiensis in complex with substrate and product analogs. Through structural analyses, mutagenesis, and activity measurements, a substrate-binding mode is proposed, and several features critical for catalysis are elucidated.

21 February 2020 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
CCChun-Chi Chen
Chun-Chi Chen
LDLonghai Dai
Longhai Dai
LMLixin Ma
Lixin Ma
RGRey-Ting Guo
Rey-Ting Guo

20 May 2021 in Nature Catalysis
Verified
Journal Article
Closed access
PDF file
CCChun-Chi Chen
Chun-Chi Chen
XHXu Han
Xu Han
XLXian Li
Xian Li
PJPengcheng Jiang
Pengcheng Jiang
DNDu Niu
Du Niu
RGRey-Ting Guo
Rey-Ting Guo

25 February 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
KLKai Li
Kai Li
LSLici A. Schurig-Briccio
Lici A. Schurig-Briccio
XFXinxin Feng
Xinxin Feng
AUAshutosh Upadhyay
Ashutosh Upadhyay
VPVenugopal Pujari
Venugopal Pujari
EOEric Oldfield
Eric Oldfield
We report the discovery of a series of new drug leads that have potent activity against Mycobacterium tuberculosis as well as against other bacteria, fungi, and a malaria parasite. The compounds are analogues of the new tuberculosis (TB) drug SQ109 (1), which has been reported to act by inhibiting a transporter called MmpL3, involved in cell wall biosynthesis. We show that 1 and the new compounds also target enzymes involved in menaquinone biosynthesis and electron transport, inhibiting respiration and ATP biosynthesis, and are uncouplers, collapsing the pH gradient and membrane potential used to power transporters. The result of such multitarget inhibition is potent inhibition of TB cell growth, as well as very low rates of spontaneous drug resistance. Several targets are absent in humans but are present in other bacteria, as well as in malaria parasites, whose growth is also inhibited.

24 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYu Yang
Yu Yang
JMJian Min
Jian Min
TXTing Xue
Ting Xue
PJPengcheng Jiang
Pengcheng Jiang
XLXin Liu
Xin Liu
RGRey-Ting Guo
Rey-Ting Guo
Poly(butylene adipate-co-terephthalate) (PBAT), a polyester made of terephthalic acid (TPA), 1,4-butanediol, and adipic acid, is extensively utilized in plastic production and has accumulated globally as environmental waste. Biodegradation is an attractive strategy to manage PBAT, but an effective PBAT-degrading enzyme is required. Here, we demonstrate that cutinases are highly potent enzymes that can completely decompose PBAT films in 48 h. We further show that the engineered cutinases, by applying a double mutation strategy to render a more flexible substrate-binding pocket exhibit higher decomposition rates. Notably, these variants produce TPA as a major end-product, which is beneficial feature for the future recycling economy. The crystal structures of wild type and double mutation of a cutinase from Thermobifida fusca in complex with a substrate analogue are also solved, elucidating their substrate-binding modes. These structural and biochemical analyses enable us to propose the mechanism of cutinase-mediated PBAT degradation.

12 June 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RGRey-Ting Guo
Rey-Ting Guo
RCRong Cao
Rong Cao
梁博煌 Liang梁博煌 Liang
梁博煌 Liang
TKTzu-Ping Ko
Tzu-Ping Ko
TCTao-Hsin Chang
Tao-Hsin Chang
AWAndrew H.-J. Wang
Andrew H.-J. Wang
Bisphosphonate drugs (e.g., Fosamax and Zometa) are thought to act primarily by inhibiting farnesyl diphosphate synthase (FPPS), resulting in decreased prenylation of small GTPases. Here, we show that some bisphosphonates can also inhibit geranylgeranyl diphosphate synthase (GGPPS), as well as undecaprenyl diphosphate synthase (UPPS), a cis -prenyltransferase of interest as a target for antibacterial therapy. Our results on GGPPS (10 structures) show that there are three bisphosphonate-binding sites, consisting of FPP or isopentenyl diphosphate substrate-binding sites together with a GGPP product- or inhibitor-binding site. In UPPS, there are a total of four binding sites (in five structures). These results are of general interest because they provide the first structures of GGPPS- and UPPS-inhibitor complexes, potentially important drug targets, in addition to revealing a remarkably broad spectrum of binding modes not seen in FPPS inhibition.